Bacterial And Plasmid Vectors Global Market Report 2024

The bacterial and plasmid vectors market size has grown rapidly in recent years. It will grow from $0.65 billion in 2023 to $0.73 billion in 2024 at a compound annual growth rate (CAGR) of 13.2%. The historical growth in this context is primarily due to several contributing factors such as the increasing prevalence of chronic diseases, a rise in infectious diseases, the aging population, higher healthcare expenditures, government-led initiatives, and an enhanced awareness of preventive healthcare measures.

The bacterial and plasmid vectors market size is expected to see strong growth in the next few years. It will grow to $1.17 billion in 2028 at a compound annual growth rate (CAGR) of 12.4%. Anticipated growth in the upcoming period can be linked to several key factors such as an increasing demand for point-of-care testing, advancements in gene and cell therapy, the expanding realm of synthetic biology, the adoption of CRISPR-Cas technology, amplified bioproduction, and the widening scope of applications in environmental and agricultural sectors. Additionally, the growth is expected to be driven by the expansion of biomanufacturing and a growing focus on personalized medicine. Notable trends projected in the forecast period encompass customized vector solutions, a heightened emphasis on safety and ethical considerations, advancements in vector delivery methods, data integration and analysis, exploration of viral vector alternatives, the provision of vector customization services, and optimization of vector delivery techniques.

The bacterial & plasmid vectors market is expected to witness increased demand in the forthcoming years due to the rising prevalence of cancer and infectious diseases. Bacteria serve as essential vectors for delivering recombinant proteins into target cells, aiding in the treatment of cancer and various infectious diseases. The World Health Organization (WHO) reports that cancer stands as the second leading cause of global mortality. In 2020, the worldwide cancer burden escalated to 19.3 million new cases, with a projected increase to 28.4 million new cases by 2040. This upward trend in cancer cases, coupled with the surge in various infectious diseases, is anticipated to drive the need for bacterial and plasmid vectors in gene therapy, thereby contributing to the market's growth.

The primary categories in bacterial and plasmid vectors include E. coli expression vectors and other bacterial expression vectors. The E. coli expression system enables swift recombinant protein expression and subsequent cost-effective large-scale production. It is particularly advantageous for expressing antigens and functional proteins that are non-glycosylated. These techniques find applications in genetics, molecular biology, bioinformatics, and various sectors including hospitals, home care, specialty clinics, and others.

The bacterial and plasmid vectors market research report is one of a series of new reports that provides bacterial and plasmid vectors market statistics, including bacterial and plasmid vectors industry global market size, regional shares, competitors with a bacterial and plasmid vectors market share, detailed bacterial and plasmid vectors market segments, market trends and opportunities, and any further data you may need to thrive in the bacterial and plasmid vectors industry. This bacterial and plasmid vectors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The growth of the bacterial and plasmid vectors market is expected to be propelled by the increasing number of clinical trials. Clinical trials refer to research studies involving human volunteers aimed at assessing the safety and efficacy of medical treatments, interventions, drugs, therapies, devices, or diagnostic procedures. These trials specifically evaluate the safety and effectiveness of Bacterial and Plasmid Vectors when used as part of therapeutic interventions, typically involving testing the vectors in human subjects to assess their ability to deliver therapeutic genes or gene-editing tools to target cells without causing harm. For instance, a report from Xtalks, a Canada-based digital health company, revealed that by May 17, 2023, a total of 452,604 clinical studies were registered on ClinicalTrials.gov, with 64,838 actively seeking participants. This marked a substantial increase compared to the more than 365,000 registered trials reported in early 2021. The rising number of clinical trials is a key driver stimulating the growth of the bacterial and plasmid vectors market.

The bacterial & plasmid vector market growth during the forecast period is expected to be constrained by the high cost associated with gene therapy. Gene therapy involves the use of authentic genes to prevent or treat diseases, using bacteria or plasmids as vectors. The expenses linked to gene therapy treatments approved by the Food and Drug Administration (FDA) range between $0.3 million and $2.1 million. For instance, Luxturna, a gene therapy targeting certain inherited retinal diseases (IRDs), costs approximately $0.4 million per eye, and LentiGlobin by Bluebird Bio, designed to increase hemoglobin levels, is priced around $2.1 million. The elevated costs of gene therapy treatments are primarily attributed to rigorous government regulations, lengthy approval procedures, and the expenses related to production. As a result, the substantial cost of gene therapy is poised to impede the growth of the bacterial & plasmid vector market in the near future.

In the bacterial and plasmid vectors market, many companies are pivoting their focus towards intensifying mergers and acquisitions to expand their production capabilities. Major industry leaders are engaging in joint ventures or acquiring smaller or mid-sized companies to obtain new expertise or to access novel markets. For example, Vectalys, a France-based company specializing in the production and distribution of lentiviral vectors for gene delivery, and FlashCell, a firm focused on engineering non-integrating lentiviral-delivered RNA therapeutics, declared their merger to establish a new entity known as Flash Therapeutics, dedicated to gene therapy.

Prominent companies in the bacterial and plasmid vectors market are introducing advanced automated platforms like the Biotage PhyPrep to streamline the purification process, reducing the reliance on manual labor. The Biotage PhyPrep is an automated system specifically engineered for the purification of plasmid DNA. For instance, in June 2021, Biotage, a technology company based in Sweden focused on workflow solutions and products, launched the Biotage PhyPrep - an innovative automated platform crafted for the purification of plasmid DNA. This system not only minimizes the repetitive manual tasks encountered by laboratory personnel but also utilizes PhyTip columns and their dual flow chromatography capabilities to produce high-quality, supercoiled, transfection-grade plasmid DNA free from endotoxins. The Biotage PhyPrep represents an automated platform designed for large-scale plasmid purification, covering Maxi, Mega, and Giga levels.

In February 2021, Catalent, a pharmaceutical company based in the United States, completed the acquisition of Delphi Genetics, a contract development and manufacturing company located in Belgium. The specific financial details of the acquisition were not disclosed. This strategic move by Catalent aims to bolster its plasmid capabilities in the United States, particularly at its Rockville facility. Delphi Genetics specializes in offering services related to plasmid DNA (pDNA), specifically within the cell and gene therapy sector as a Contract Development and Manufacturing Organization (CDMO).

Major companies operating in the bacterial and plasmid vectors market include Sigma-Aldrich Inc., ATUM, QIAGEN N.V., Promega Corporation, Thermo Fisher Scientific Inc., GenScript Biotech Corporation, Takara Bio Inc., IBA GmbH, Bio-Rad Laboratories, New England Biolabs, Agilent Technologies, Life Technologies Corporation, Clontech Laboratories Inc., DNA TwoPointO Inc., F. Hoffmann-La Roche Ltd, Norgen Biotek Corporation, Tecan Group Ltd, Biotage, BioCat GmbH, BioChain Institute Inc., BioLegend, BioVision Inc., Cell Applications Inc., Cell Biolabs Inc., Cell Signaling Technology Inc., Clontech Laboratories Inc., Creative Biogene, Creative Biomart, Creative Diagnostics, Enzo Life Sciences Inc.

North America was the largest region in the bacterial & plasmid vectors market in 2023. The Middle East is expected to be the fastest-growing region in the global bacterial & plasmid vectors market share during the forecast period. The regions covered in the bacterial and plasmid vectors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the bacterial and plasmid vectors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The bacterial and plasmid vectors market includes revenues earned by entities by cloning, transferring, and manipulating genes. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.